Member Info for sharehunter3

good to see a blue day today ,

was interesting to watch the size of some of share buys today ,to see the larger share buys loading up on sells

like the size of some of buys today ,picking up shares after earlier sells this morning .

France share price now gone blue again .

still hoping for £15 a share ,seeing plenty of sellers cleared ,in my view important to see these sellers cleared ,before another move up is seen .

France now blue again

https://www.google.com/search?q=novacyt+job+offers&oq=novacyt+job+offers&aqs=chrome..69i57.8751j0j9&sourceid=chrome&ie=UTF-8&ibp=htl;jobs&sa=X&ved=2ahUKEwi9jM33yuPsAhW0p3EKHexaCyEQiYsCKAB6BAgMEAQ&sxsrf=ALeKk01ljSUk-GQUY2kc2qaGBJ7n3wySMQ:1604310659195#htivrt=jobs&htidocid=fVYfB0ULiOsx2kyIAAAAAA%3D%3D&fpstate=tldetailoro

when it looks not even a tweet on a contract win of nearly £2 million .
only for good research being posted , might not have not found out ,of this contract .

Https://www.hsj.co.uk/coronavirus/nhs-doubles-covid-test-capacity-in-three-days-as-tandt-looks-set-to-hit-500k-target/7028726.article

EXMEX ,Thanks for post ,and your other good posts

Harveyspecter ,looked in here yesterday seen 15,10 post ,Please don’t do a placing xD

how much cash does ,Tern have ,how much expenses , be interested in views from people who have more knowledge of
Tern ,

with ncyt could be released at any time ,maybe around end of month ,we do not know when ,

if this accurate ,looks like not even a tweet on a contract of nearly £2 million ,how money ,and much sales have ncyt coming in

https://twitter.com/primerdesignltd

also the tweet on 21st October

https://twitter.com/MicrogenBioProd

exmex did not see it ,assume has been removed before seen this thread

now curious , as find your posts helpful is there any other way you could word your post

Wilson63, good research ,also thought post on 28th interesting

https://twitter.com/MicrogenBioProd

If this accurate on contract win of nearly £2milliion ,and no rns from ncyt ,
how many other companys would have issued a rns with a contract win .

Afterburn450 , have only seen this ,thanks for posting , so many good researchers on ncyt share board

https://testingmethods.crowdicity.com/post/3389610

PROP5 , hope this new test will more one of the more accurate ,



Launch of COVID-19 antibody test



Paris, France and Camberley, UK - 29 September 2020 - Novacyt, an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2 derived from plasma and serum samples.



The test has been launched by Microgen Bioproducts Limited (Microgen), which is part of Novacyt's protein diagnostics division Lab21. The new antibody test complements Novacyt's existing COVID-19 product portfolio, in particular the Company's polymerase chain reaction (PCR) test for COVID-19, to provide clinicians with the diagnostic tools to detect and differentiate between active and prior SARS-CoV-2 infections in patients.



The new antibody test has been validated in a study where 1,673 patient samples (112 positive samples and 1,561 negative samples) were evaluated. The test demonstrated 100% sensitivity in patients that were tested at 14 days after testing positive for COVID-19 by a PCR test. The antibody test also demonstrated 99.4% specificity.



The ELISA test has been designed for use in all established central laboratories and follows a standard ELISA protocol that makes it compatible with most 96-well plate automation systems. Novacyt has sufficient manufacturing capacity to deliver more than three million antibody tests per month initially and the Company is working with its manufacturing partner to ensure this can be increased depending on demand.



Graham Mullis, Chief Executive Officer of Novacyt, commented:

"Novacyt remains committed to supporting the global response to COVID-19 through the delivery of high performance diagnostics. We continue to strengthen our product offering in COVID-19 testing as demand continues and we are delighted to launch an antibody test. We believe an antibody test plays an important role in aiding the diagnosis of COVID-19, as well as increasing our understanding of the disease through screening of populations for infection rates and immunity."

SO much recruitment so many jobs been advertised

The Company intends to invest both organically and through M&A in establishing a direct sales force in certain markets. Novacyt plans to establish a strong commercial infrastructure in the UK, where a significant investment in the diagnostics market is taking place. In addition, it is in the process of evaluating the best model to operate in the US, the world's largest IVD market. It is also considering certain key mainland European markets. In the rest of the world, Novacyt will continue to develop its successful distributor and partnership sales model.